Al-Janabi A - Search Results

1

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.

Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. Al-Janabi A, et al. Br J Dermatol. 2019 Jun;180(6):1348-1351. doi: 10.1111/bjd.17624. Epub 2019 Mar 27. Br J Dermatol. 2019. PMID: 30632140 Clinical Trial.

2

Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal.

Al-Janabi A, Warren RB. Al-Janabi A, et al. Br J Dermatol. 2020 Aug;183(2):220-221. doi: 10.1111/bjd.18856. Epub 2020 Feb 13. Br J Dermatol. 2020. PMID: 31899817 No abstract available.

3

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.

Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths CEM, Warren RB. Al-Janabi A, et al. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1440-1448. doi: 10.1111/jdv.16246. Epub 2020 Feb 27. J Eur Acad Dermatol Venereol. 2020. PMID: 31997406 Review.

4

Update on risankizumab for the treatment of moderate to severe psoriasis.

Al-Janabi A, Warren RB. Al-Janabi A, et al. Expert Opin Biol Ther. 2020 Nov;20(11):1245-1251. doi: 10.1080/14712598.2020.1822813. Epub 2020 Sep 25. Expert Opin Biol Ther. 2020. PMID: 32933320 Review.

5

Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.

Haw WY, Al-Janabi A, Arents BWM, Asfour L, Exton LS, Grindlay D, Khan SS, Manounah L, Yen H, Chi CC, van Zuuren EJ, Flohr C, Yiu ZZN. Haw WY, et al. Br J Dermatol. 2021 Oct;185(4):736-744. doi: 10.1111/bjd.20428. Epub 2021 Jul 5. Br J Dermatol. 2021. PMID: 33937976 Review.

6

Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.

Al-Janabi A, Littlewood Z, Griffiths CEM, Hunter HJA, Chinoy H, Moriarty C, Yiu ZZN, Warren RB. Al-Janabi A, et al. Br J Dermatol. 2021 Sep;185(3):646-648. doi: 10.1111/bjd.20479. Epub 2021 Jun 4. Br J Dermatol. 2021. PMID: 33982284 Free PMC article. No abstract available.

7

Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.

Ali Z, Matthews R, Al-Janabi A, Warren RB. Ali Z, et al. Expert Rev Clin Immunol. 2021 Oct;17(10):1073-1081. doi: 10.1080/1744666X.2021.1967748. Epub 2021 Aug 20. Expert Rev Clin Immunol. 2021. PMID: 34384327 Review.

8

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.

Al-Janabi A, Yiu ZZN. Al-Janabi A, et al. Psoriasis (Auckl). 2022 Jan 6;12:1-14. doi: 10.2147/PTT.S328575. eCollection 2022. Psoriasis (Auckl). 2022. PMID: 35024352 Free PMC article. Review.

9

Paradoxical eczema in patients with psoriasis receiving biologics: a case series.

Al-Janabi A, Foulkes AC, Griffiths CEM, Warren RB. Al-Janabi A, et al. Clin Exp Dermatol. 2022 Jun;47(6):1174-1178. doi: 10.1111/ced.15130. Epub 2022 Mar 10. Clin Exp Dermatol. 2022. PMID: 35150003 Free PMC article.

10

The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.

Al-Janabi A, Ra A, Littlewood Z, Foulkes AC, Hunter HJA, Chinoy H, Moriarty CA, Hyrich KL, Limdi JK, Yiu ZZN, Griffiths CEM, Warren RB. Al-Janabi A, et al. Br J Dermatol. 2023 Mar 30;188(4):542-551. doi: 10.1093/bjd/ljac109. Br J Dermatol. 2023. PMID: 36695406

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters